In terms of our findings, we may need to take into consideration the expression levels of AEBP1 in patients’ tumor samples when planning clinical trials of MTOR inhibitors on GBM or evaluating clinical responses of MTOR inhibitors in the treatment of GBM. Here, MTOR is linked to glioblastoma.